» Articles » PMID: 27859913

COPD Assessment Test for Measurement of Health Status in Patients with Idiopathic Pulmonary Fibrosis: A Cross-sectional Study

Overview
Journal Respirology
Specialty Pulmonary Medicine
Date 2016 Nov 19
PMID 27859913
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: The COPD Assessment Test (CAT) has been reported to have potential utility for measuring health status of idiopathic pulmonary fibrosis (IPF). Although the CAT has been developed for the assessment of COPD patients, it has not been fully evaluated exclusively in IPF. This study was designed to evaluate the validity of the CAT in IPF.

Methods: The clinical data for 106 consecutive subjects with newly diagnosed IPF who completed pulmonary function tests, partial pressure of oxygen in arterial blood (PaO ) at rest, 6-min walk test (6MWT), CAT, St George's Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC) dyspnoea grade and Hospital Anxiety and Depression Scale (HADS), were analysed. We assessed the validity of the CAT in comparison with the SGRQ.

Results: The present subjects showed mild to moderate restrictive impairment on spirometry. Mean CAT score and total SGRQ were 12.8 ± 8.0 and 30.8 ± 17.7, respectively. The concurrent validity of the CAT score in comparison with the SGRQ total score was significant (r = 0.72, P < 0.001). Internal consistency (Cronbach's α = 0.869) and repeatability over 3 months (intraclass correlation coefficient = 0.742) of the CAT were also significant. Single regression analysis showed that the CAT had significant construct validity. In multiple regression analysis, mMRC, PaO at rest, minimum SpO during 6MWT and anxiety of HADS were independent predictors for the CAT.

Conclusions: The CAT is a valid health status measurement in IPF patients. Multiple regression analysis showed that the CAT was significantly correlated with dyspnoea severity, oxygenation impairment and anxiety.

Citing Articles

Health-related quality of life and health state utility value in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Zhao G, Lei S, Li Y, Feng Z, Li J Health Qual Life Outcomes. 2025; 23(1):3.

PMID: 39757157 PMC: 11702038. DOI: 10.1186/s12955-024-02326-y.


Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy.

Kataoka K, Oda K, Takizawa H, Ogura T, Miyamoto A, Inoue Y Sci Rep. 2023; 13(1):13664.

PMID: 37608014 PMC: 10444790. DOI: 10.1038/s41598-023-40508-8.


Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis.

Takei R, Matsuda T, Fukihara J, Sasano H, Yamano Y, Yokoyama T Front Med (Lausanne). 2023; 10:1067149.

PMID: 37457568 PMC: 10347395. DOI: 10.3389/fmed.2023.1067149.


SARC-F scores can predict health status and daily activity in patients with idiopathic pulmonary fibrosis.

Ohkubo H, Fujita K, Nakano A, Amakusa Y, Mori Y, Fukumitsu K J Thorac Dis. 2022; 14(11):4309-4318.

PMID: 36524076 PMC: 9745519. DOI: 10.21037/jtd-22-813.


Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates.

Hoyer N, Prior T, Bendstrup E, Shaker S BMJ Open Respir Res. 2022; 9(1).

PMID: 35798532 PMC: 9263910. DOI: 10.1136/bmjresp-2022-001276.